# US 2024/0189295 A1 · Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189295 A1
- Document ID: US20240189295A1
- Status: Published application
- Kind: A1
- Application number: 18/582,273
- Filed: 2024-02-20
- Published: 2024-06-13
- Earliest claimed: 2016-09-07
- Assignees: The Children's Hospital of Philadelphia
- Applicants: The Children's Hospital of Philadelphia
- Inventors: Hakon Hakonarson; Charlly Kao
- Web page: https://patentgrep.com/patent/US20240189295A1

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).

## Claims

### Claim 1

A method of treating anorexia nervosa (AN) in a subject comprising administering a therapeutically effective amount of a nonselective metabotropic glutamate receptor (mGluR) activator to a subject having at least one genetic alteration in a mGluR network gene, thereby treating AN.

### Claim 2

A method of treating binge eating disorder (BED) in a subject comprising administering a therapeutically effective amount of a nonselective metabotropic glutamate receptor (mGluR) activator to a subject having at least one genetic alteration in a mGluR network gene, thereby treating BED.

### Claim 3

A method of treating anorexia nervosa (AN) and binge eating disorder (BED) in a subject comprising administering a therapeutically effective amount of a nonselective metabotropic glutamate receptor (mGluR) activator to a subject having at least one genetic alteration in a mGluR network gene, thereby treating AN and BED.

### Claim 4

The method of any of the preceding claims, wherein the genetic alteration is a copy number variation (CNV).

### Claim 5 (depends on 4)

The method of claim 4, wherein the CNV is a deletion or a duplication.

### Claim 6

The method of any one of the preceding claims, wherein the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes.

### Claim 7

The method of any one of the preceding claims, wherein the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes.

### Claim 8

The method of any one of the preceding claims, wherein the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.

### Claim 9

The method of any one of the preceding claims, wherein the genetic alteration is not in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

### Claim 10

The method of any one of the preceding claims, wherein the subject has a genetic alteration in at least two mGluR network genes.

### Claim 11

The method of any one of the preceding claims, wherein the subject has the bingeing and/or purging subtype of AN.

### Claim 12

The method of any one of the preceding claims, wherein the subject has the restricting subtype of AN.

### Claim 13

The method of any one of the preceding claims, wherein the subject is a pediatric or adolescent subject, such as a subject between the ages of 5 and 17, 8 and 17, 5 and 12, 5 and 8, 8 and 12, 13 and 17, 13 and 18, or 12 and 17.

### Claim 14

The method of any one of the preceding claims, wherein the subject is an adult.

### Claim 15

The method of any one of the preceding claims, wherein the nonselective mGluR activator is fasoracetam.

### Claim 16 (depends on 15)

The method of claim 15, wherein fasoracetam is fasoracetam monohydrate.

### Claim 17 (depends on 15, 16)

The method of claim 15 or claim 16, wherein the fasoracetam is administered at a dose of 50-400 mg, such as 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, and wherein the dose is administered once, twice, or three times daily.

### Claim 18 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg, or 400 mg twice daily, such as 100-200 mg twice daily.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the subject is already taking or is administered one or more antidepressant, anxiolytic or anti-psychotic.

### Claim 20 (depends on 19)

The method of claim 19, wherein the antidepressant is fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, norepinephrine and dopamine reuptake inhibitors, or monoamine oxidase inhibitors.

### Claim 21 (depends on 19, 20)

The method of claim 19 or claim 20, wherein the anxiolytic is a barbiturate, pregabalin, or benzodiazepines, including chlordiazepoxide, clorazepate, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam, or midazolam.

### Claim 22 (depends on 19, 20, 21)

The method of any one of claims 19-21, wherein the anti-psychotic is olanzapine, quetiapine, aripiprazole or risperidone.

### Claim 23

The method of any one of the preceding claims, wherein the activator is administered in combination with non-pharmaceutical therapy, such as brain stimulation, for example vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetic seizure therapy, and/or deep brain stimulation.

### Claim 24

The method of any one of the preceding claims, wherein the genetic alteration is detected by a process comprising administering a genetic test comprising obtaining a sample from the subject, optionally isolating nucleic acid from the sample, optionally amplifying the nucleic acid, and analyzing the nucleic acid for a genetic alteration in at least one mGluR network gene.

### Claim 25 (depends on 24)

The method of claim 24, further comprising obtaining results of the genetic test prior to initial administration of the activator.

### Claim 26 (depends on 24, 25)

The method of any one of claim 24 or claim 25, wherein the genetic test comprises analyzing the nucleic acid for a CNV or SNV in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes.

### Claim 27 (depends on 24, 25, 26)

The method of any one of claims 24-26, wherein the genetic test comprises analyzing the nucleic acid for a CNV or SNV in at least 2, 3, 4, 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes.

### Claim 28 (depends on 24, 25, 26, 27)

The method of any one of claims 24-27, wherein the genetic test comprises analyzing the nucleic acid for a CNV or SNV in at least 2, 3, 4, 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.

### Claim 29 (depends on 24, 25, 26, 27, 28)

The method of any one of claims 24-28, wherein the genetic test does not assess CNVs or SNVs in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

### Claim 30

A method of treating binge eating disorder (BED) in a subject comprising administering a nonselective mGluR activator to the subject, thereby treating BED.

### Claim 31

A method of treating anorexia nervosa (AN) in a subject comprising administering a nonselective mGluR activator to the subject, thereby treating AN.

### Claim 32

A method of treating BED and AN in a subject comprising administering an a nonselective mGluR activator to the subject, thereby treating BED and AN.

### Claim 33 (depends on 30, 31, 32)

The method of any one of claims 30-32, wherein the nonselective mGluR activator is fasoracetam.

### Claim 34 (depends on 33)

The method of claim 33, wherein the fasoracetam is fasoracetam monohydrate.

### Claim 35 (depends on 33, 34)

The method of claim 33 or claim 34, wherein the fasoracetam is administered at a dose of 50-400 mg, such as 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, and wherein the dose is administered once, twice, or three times daily, thereby treating AN.

### Claim 36 (depends on 33, 34, 35)

The method of any one of claims 33-35, wherein the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg, or 400 mg twice daily, such as 100-200 mg twice daily.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 30-36, wherein the subject has at least one genetic alteration in an mGluR network gene.

### Claim 38 (depends on 37)

The method of claim 37, wherein the genetic alteration is a CNV.

### Claim 39 (depends on 38)

The method of claim 38, wherein the CNV is a deletion or a duplication.

### Claim 40 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 30-39, wherein the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes.

### Claim 41 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 30-40, wherein the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes.

### Claim 42 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 30-41, wherein the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.

### Claim 43 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 30-42, wherein the genetic alteration is not in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

### Claim 44 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 30-43, wherein the subject has a genetic alteration in at least two mGluR network genes.

### Claim 45 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 30-44, wherein the subject has the bingeing and/or purging subtype of AN.

### Claim 46 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 30-44, wherein the subject has the restricting subtype of AN.

### Claim 47 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 30-46, wherein the subject is a pediatric or adolescent subject, such as a subject between the ages of 5 and 17, 8 and 17, 5 and 12, 5 and 8, 8 and 12, or 12 and 17.

### Claim 48 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 30-46, wherein the subject is an adult subject.

### Claim 49 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 30-48, wherein the subject is already taking or is administered one or more antidepressant, anxiolytic or anti-psychotic.

### Claim 50 (depends on 49)

The method of claim 49, wherein the antidepressant is fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, norepinephrine and dopamine reuptake inhibitors, or monoamine oxidase inhibitors.

### Claim 51 (depends on 49, 50)

The method of claim 49 or claim 50, wherein the anxiolytic is a barbiturate, pregabalin, or benzodiazepines, including chlordiazepoxide, clorazepate, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam, or midazolam.

### Claim 52 (depends on 49, 50, 51)

The method of any one of claims 49-51, wherein the anti-psychotic is olanzapine, quetiapine, aripiprazole or risperidone.

### Claim 53 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 33-52, wherein the fasoracetam is administered in combination with non-pharmaceutical therapy, such as brain stimulation, for example vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetic seizure therapy, and/or deep brain stimulation.

### Claim 54 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 37-53, wherein the genetic alteration is detected by a process comprising administering a genetic test comprising obtaining a sample from the subject, optionally isolating nucleic acid from the sample, optionally amplifying the nucleic acid, and analyzing the nucleic acid for a genetic alteration in at least one mGluR network gene.

### Claim 55 (depends on 54)

The method of claim 54, wherein the method further comprises obtaining results of the genetic test prior to initial administration of the activator.

### Claim 56 (depends on 54, 55)

The method of claim 54 or 55, wherein the genetic test comprises analyzing the nucleic acid for a CNV or SNV in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes.

### Claim 57 (depends on 54, 55, 56)

The method of any one of claims 54-56, wherein the genetic test comprises analyzing the nucleic acid for a CNV or SNV in at least 2, 3, 4, 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes.

### Claim 58 (depends on 54, 55, 56, 57, 58)

The method of any one of claims 54-58, wherein the genetic test comprises analyzing the nucleic acid for a CNV or SNV in at least 2, 3, 4, 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.

### Claim 59 (depends on 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 54-60, wherein the genetic test does not assess CNVs or SNVs in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

### Claim 60 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 31-59, wherein the subject does not have a CNV or SNV in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

### Claim 61

A method for diagnosing anorexia nervosa (AN) in a subject, the method comprising:
a) obtaining a biological sample from the subject;
b) assaying nucleic acid from the sample to determine whether a genetic alteration is present in one or more genes in the mGluR network; and
c) diagnosing the subject with AN if a genetic alteration is present in one or more genes in the mGluR network.

### Claim 62

A method for diagnosing binge eating disorder (BED) in a subject, the method comprising:
a) obtaining a biological sample from the subject;
b) assaying nucleic acid from the sample to determine whether a genetic alteration is present in one or more genes in the mGluR network; and
c) diagnosing the subject with BED if a genetic alteration is present in one or more genes in the mGluR network.

### Claim 63 (depends on 61, 62)

The method of claim 61 or claim 62, wherein the genetic alteration is a CNV.

### Claim 64 (depends on 63)

The method of claim 63, wherein the CNV is a deletion or a duplication.

### Claim 65 (depends on 61, 62, 63, 64)

The method of any one of claims 61-64, wherein the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes.

### Claim 66 (depends on 61, 62, 63, 64, 65)

The method of any one of claims 61-65, wherein the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes.

### Claim 67 (depends on 61, 62, 63, 64, 65, 66)

The method of any one of claims 61-66, wherein the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.

### Claim 68 (depends on 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 61-67, wherein the genetic alteration is not in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

### Claim 69 (depends on 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 61-68, wherein the subject has a genetic alteration in at least two mGluR network genes.

### Claim 70 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 61-69, wherein the subject has the bingeing and/or purging subtype of AN.

### Claim 71 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 61-69, wherein the subject has the restricting subtype of AN.

### Claim 72 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any of claims 61-71, wherein the subject is a pediatric or adolescent subject between the ages of 5 and 17, 8 and 17, 5 and 12, 5 and 8, 8 and 12, 12 and 17, 13 and 18 or 13 and 17.

### Claim 73 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any of claims 61-71, wherein the subject is an adult subject.

### Claim 74 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 61-73, wherein the method further comprises providing a report comprising suggested treatment(s) for AN and/or BED based upon the genetic alteration(s) identified in the method.

### Claim 75 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 61-74, wherein the method further comprises prescribing or administering an effective amount of a non-selective mGluR activator to the diagnosed subject.

### Claim 76 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 61-75, wherein the diagnosed subject is prescribed, administered, or is already taking one or more antidepressant, anxiolytic or anti-psychotic.

### Claim 77 (depends on 76)

The method of claim 76, wherein the antidepressant is fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, norepinephrine and dopamine reuptake inhibitors, or monoamine oxidase inhibitors.

### Claim 78 (depends on 76, 77)

The method of claim 76 or claim 77, wherein the anxiolytic is a barbiturate, pregabalin, or benzodiazepines, including chlordiazepoxide, clorazepate, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam, or midazolam.

### Claim 79 (depends on 76, 77, 78)

The method of any one of claims 76-78, wherein the anti-psychotic is olanzapine, quetiapine, aripiprazole or risperidone.

### Claim 80 (depends on 76, 77, 78, 79)

The method of any one of claims 76-79, wherein the nonselective mGluR activator is fasoracetam.

### Claim 81 (depends on 80)

The method of claim 80, wherein the fasoracetam is fasoracetam monohydrate.

### Claim 82 (depends on 80, 81)

The method of claim 80 or claim 81, wherein the fasoracetam is prescribed or administered at a dose of 50-400 mg, such as 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, and wherein the dose is administered once, twice, or three times daily.

### Claim 83 (depends on 80, 81)

The method of claim 80 or claim 81, wherein the fasoracetam is prescribed or administered at a dose of 100 mg, 200 mg, 300 mg, or 400 mg twice daily, such as 100-200 mg twice daily.

### Claim 84

The method of any one of the preceding claims, wherein the genetic alteration is in one or more genes in the mGluR network at the corresponding chromosomal regions listed in FIGS. 1 to 3.

### Claim 85

A method for determining whether a subject is susceptible to developing anorexia nervosa (AN) and/or binge eating disorder (BED), the method comprising:
a) obtaining a biological sample from the subject;
b) assaying nucleic acid from the sample to determine whether a genetic alteration in one or more genes in the mGluR network is present in the nucleic acid; and
c) determining that the subject is susceptible to developing AN and/or BED if a genetic alteration is present in one or more one or more genes in the mGluR network.

### Claim 86 (depends on 85)

The method of claim 85, wherein the genetic alteration is a CNV.

### Claim 87 (depends on 86)

The method of claim 86, wherein the CNV is a deletion or a duplication.

### Claim 88 (depends on 85, 86, 87)

The method of any one of claims 85-87, wherein the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes.

### Claim 89 (depends on 85, 86, 87, 88)

The method of any one of claims 85-88, wherein the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes.

### Claim 90 (depends on 85, 86, 87, 88, 89)

The method of any one of claims 85-89, wherein the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.

### Claim 91 (depends on 85, 86, 87, 88, 89, 90)

The method of any one of claims 85-90, wherein the genetic alteration is not in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

### Claim 92 (depends on 85, 86, 87, 88, 89, 90, 91)

The method of any one of claims 85-91, wherein the subject has at least one genetic alteration in at least two mGluR network genes.

### Claim 93 (depends on 85, 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 85-92, wherein the subject is susceptible to the bingeing and/or purging subtype of AN.

### Claim 94 (depends on 85, 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 85-92, wherein the subject is susceptible to the restricting subtype of AN.

### Claim 95 (depends on 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The method of any of claims 85-94, wherein the subject is a pediatric or adolescent subject between the ages of 5 and 17, 8 and 17, 5 and 12, 5 and 8, 8 and 12, 12 and 17 or 13 and 17.

### Claim 96 (depends on 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The method of any of claims 85-94, wherein the subject is an adult subject.

### Claim 97 (depends on 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 85-96, wherein the method further comprises providing a report comprising suggested treatment(s) for AN and/or BED based upon the genetic alteration(s) identified in the method.

### Claim 98 (depends on 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 85-97, wherein the method further comprises prescribing or administering an effective amount of a nonselective mGluR activator to the susceptible subject.

### Claim 99 (depends on 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method of any one of claim 85-98, wherein the susceptible subject is prescribed, administered, or is already taking one or more antidepressant, anxiolytic or anti-psychotic.

### Claim 100 (depends on 99)

The method of claim 99, wherein the antidepressant is fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, norepinephrine and dopamine reuptake inhibitors, or monoamine oxidase inhibitors.

### Claim 101 (depends on 99, 100)

The method of claim 99 or claim 100, wherein the anxiolytic is a barbiturate, pregabalin, or benzodiazepines, including chlordiazepoxide, clorazepate, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam, or midazolam.

### Claim 102 (depends on 99, 100, 101)

The method of any one of claims 99-101, wherein the anti-psychotic is olanzapine, quetiapine, aripiprazole or risperidone.

### Claim 103 (depends on 98, 99, 100, 101, 102)

The method of any one of claims 98-102, wherein the nonselective mGluR activator is fasoracetam.

### Claim 104 (depends on 103)

The method of claim 103, wherein the fasoracetam is fasoracetam monohydrate.

### Claim 105 (depends on 103, 104)

The method of claim 103 or claim 104, wherein the fasoracetam is prescribed or administered at a dose of 50-400 mg, such as 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, and wherein the dose is administered once, twice, or three times daily.

### Claim 106 (depends on 103, 104)

The method of claim 103 or claim 104, wherein the fasoracetam is prescribed or administered at a dose of 100 mg, 200 mg, 300 mg, or 400 mg twice daily, such as 100-200 mg twice daily.

### Claim 107

A system for detecting a genetic alteration related to anorexia nervosa (AN) or binge eating disorder in a subject, comprising probes specific for and capable of determining the presence of a genetic alteration in: i) at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes; ii) at least 1, 2, 3, 4, 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes; and/or iii) at least 1, 2, 3, 4, 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.

### Claim 108 (depends on 107)

The system of claim 107, wherein the genetic alteration is a point mutation, insertion, deletion, single nucleotide variation (SNV), single nucleotide polymorphism (SNP) or copy number variation (CNV).

### Claim 109 (depends on 108)

The system of claim 108, wherein the genetic alteration is a CNV.

### Claim 110 (depends on 107, 108, 109)

The system of any one of claims 107-109, wherein the system is capable of determining CNVs or SNVs at the corresponding chromosomal regions listed in FIGS. 1 to 3.

### Claim 111 (depends on 107, 108, 109, 110)

The system of any one of claims 107-110, wherein the probes are affixed to a solid support matrix, such as a chip.
